Skip to main content

Table 2 Baseline characteristics of patients according to PCSK9 stratification

From: Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study

Variables

Total (n = 1225)

PCSK9 concentration (ng/mL)

p value

 < 234.52 (n = 612)

 ≥ 234.52 (n = 613)

Clinical characteristics

 Age (years)

57.8 ± 10.1

57.1 ± 10.1

58.4 ± 10.0

0.027

 Male sex

833 (68.0)

469 (76.6)

364 (59.4)

 < 0.001

 BMI (kg/m2)

25.9 ± 3.3

26.0 ± 3.5

25.8 ± 3.2

0.217

 Hypertension

854 (69.7)

424 (69.3)

430 (70.1)

0.742

 Family history of CAD

289 (23.6)

126 (20.6)

163 (26.6)

0.013

 Diabetes mellites

377 (30.8)

180 (29.4)

197 (32.1)

0.301

 Current smoker

481 (39.3)

258 (53.6)

223 (46.4)

0.038

 Drinking

284 (23.2)

159 (56.0)

125 (44.0)

0.020

Laboratory parameters

 FPG (mmol/L)

5.9 ± 1.9

5.7 ± 1.7

6.0 ± 2.1

0.012

 HbA1C (%)

6.2 ± 1.1

6.1 ± 1.0

6.3 ± 1.2

0.010

 ALT(U/L)

20 (15,29)

20 (15,28)

20 (14,30)

0.769

 Creatinine (μmol/L)

77.7 ± 17.5

77.9 ± 16.1

77.5 ± 18.8

0.680

 TC (mmol/L)

4.82 ± 0.96

4.67 ± 0.90

4.98 ± 0.99

 < 0.001

 TG (mmol/L)

1.61 (1.16,2.31)

1.55 (1.12,2.30)

1.65 (1.20,2.34)

0.226

 HDL-C (mmol/L)

1.09 ± 0.32

1.07 ± 0.33

1.12 ± 0.32

0.011

 LDL-C (mmol/L)

3.15 ± 0.85

3.00 ± 0.78

3.29 ± 0.89

 < 0.001

 Fibrinogen (μg/mL)

3.1 ± 0.8

3.0 ± 0.6

3.2 ± 0.8

 < 0.001

 NT-proBNP (pg/mL)

51.9 (31.0,109.3)

49.45 (31.2,92.5)

53.2 (30.4,130.0)

0.083

Diseased vessels

 One vessel

438 (35.8)

241 (39.4)

197 (32.1)

 

 Two vessels

365 (29.8)

173 (28.2)

192 (31.3)

 

 Three vessels

422 (34.4)

198 (32.4)

224 (36.5)

 

 LVEF (%)

64.7 ± 6.7

64.6 ± 6.9

64.8 ± 6.6

0.716

 Gensini score

27 (11,44)

25 (10,43)

28 (12,44)

0.095

Medications

 Aspirin

464 (37.9)

228 (37.3)

236 (38.5)

0.654

 Clopidogrel

130 (10.6)

61 (10.0)

69 (11.3)

0.464

 ACEI/ARB

252 (20.6)

119 (19.4)

133 (21.7)

0.330

 β-blockers

238 (19.4)

108 (17.6)

130 (21.2)

0.115

MACEs

103 (8.4)

36 (5.9)

67 (10.9)

0.001

  1. PCSK9 proprotein convertase subtilisin/kexin type 9, BMI body mass index, CAD coronary artery disease, FPG fasting plasma glucose, HbA1C hemoglobin A1C, ALT alanine aminotransferase, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MACEs major adverse cardiovascular events, p < 0.05 suggests significant difference
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840